Does Minerva Neurosciences, Inc. (NASDAQ:NERV) Have A Particularly Volatile Share Price?

Anyone researching Minerva Neurosciences, Inc. (NASDAQ:NERV) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The other type, which cannot be diversified away, is the volatility of the entire market. Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market.

Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). However, Warren Buffett said 'volatility is far from synonymous with risk' in his 2014 letter to investors. So, while useful, beta is not the only metric to consider. To use beta as an investor, you must first understand that the overall market has a beta of one. A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

View our latest analysis for Minerva Neurosciences

Advertisement

What NERV's beta value tells investors

Given that it has a beta of 1.57, we can surmise that the Minerva Neurosciences share price has been fairly sensitive to market volatility (over the last 5 years). If the past is any guide, we would expect that Minerva Neurosciences shares will rise quicker than the markets in times of optimism, but fall faster in times of pessimism. Beta is worth considering, but it's also important to consider whether Minerva Neurosciences is growing earnings and revenue. You can take a look for yourself, below.

NasdaqGM:NERV Income Statement, July 22nd 2019
NasdaqGM:NERV Income Statement, July 22nd 2019

Does NERV's size influence the expected beta?

Minerva Neurosciences is a rather small company. It has a market capitalisation of US$255m, which means it is probably under the radar of most investors. Relatively few investors can influence the price of a smaller company, compared to a large company. This could explain the high beta value, in this case.

What this means for you:

Since Minerva Neurosciences has a reasonably high beta, it's worth considering why it is so heavily influenced by broader market sentiment. For example, it might be a high growth stock or have a lot of operating leverage in its business model. This article aims to educate investors about beta values, but it's well worth looking at important company-specific fundamentals such as Minerva Neurosciences’s financial health and performance track record. I highly recommend you dive deeper by considering the following:

  1. Future Outlook: What are well-informed industry analysts predicting for NERV’s future growth? Take a look at our free research report of analyst consensus for NERV’s outlook.
  2. Past Track Record: Has NERV been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of NERV's historicals for more clarity.
  3. Other Interesting Stocks: It's worth checking to see how NERV measures up against other companies on valuation. You could start with this free list of prospective options.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

About NasdaqCM:NERV

Minerva Neurosciences

A clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases.

Slight risk with imperfect balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7065.0% undervalued
41 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$319.9636.2% undervalued
45 users have followed this narrative
8 users have commented on this narrative
15 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0541.3% undervalued
44 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
TO
Tokyo
OKTA logo
Tokyo on Okta ·

Good foundation, but now it's all about the next steps

Fair Value:US$15123.0% undervalued
90 users have followed this narrative
7 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

DC
DOCS logo
Dc12 on Doximity ·

High physician usership and impressive AI tools

Fair Value:US$33.740.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RO
Rog
CTT logo
Rog on CTT - Correios De Portugal ·

Why CTT benefits in multiple ways right now

Fair Value:€6.6710.2% undervalued
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ES
HSY logo
Esteban on Hershey ·

Hershey - fortress brand-and-scale position in U.S. confectionery: protects the downside far better than it compounds the upside

Fair Value:US$85.86111.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7446.4% undervalued
65 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9723.5% undervalued
58 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1931.2% undervalued
49 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative